Icahn School of Medicine at Mount Sinai and Champions Oncology Initiate Study Evaluating TumorGrafts’ Ability to Predict Treatment Benefit in Patients with Triple-Negative Breast Cancer

New York, NY and Hackensack, NJ – June 17, 2014 – Icahn School of Medicine at Mount Sinai and Champions Oncology (OTC : CSBR)  a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the initiation of a clinical trial evaluating the use of Champions TumorGrafts® in 100 patients with triple-negative breast cancer. The study will also include a side-by-side genomic analysis of the patients’ tumor and TumorGraft mouse avatars before and after treatment. Principal investigators from the Dubin Breast Center and Icahn Institute for Genomics are leading this effort at Mount Sinai, and the project is being coordinated through the Tisch Cancer Institute.

“Mount Sinai is at the forefront of new advancements and innovation in breast cancer treatment,” said Elisa Port, MD, Chief of Breast Surgery and Director of Dubin Breast Center at The Mount Sinai Hospital. “This trial is one of several looking at a more individualized approached to treating breast cancer patients. These findings will provide invaluable information on the best course of treatment for the individual instead of a one size fits all approach.”

In this study, researchers will create TumorGrafts and use clinical genomics to analyze tissue obtained during initial biopsies. Patients will then undergo traditional neo-adjuvant therapy and resection surgery. Clinical genomics will be performed on the tissue obtained from the resection and the TumorGraft mouse avatars, which will be compared to evaluate how closely the TumorGrafts continue to resemble the patients’ progress. The resulting TumorGrafts will also form a tumor bank that can be used for future drug research and development, with the goal of advancing therapies for patients who are resistant to the standard of care.

“This is our largest study in the use of our TumorGrafts in a specific cancer type to date, and is designed to show the high predictability of the mouse avatars for triple-negative breast cancer patients as well as further demonstrate the close resemblance of TumorGrafts to a patient’s tumor, even over time,” said Ronnie Morris, M.D., President of Champions Oncology. “We are proud to partner with the Icahn School of Medicine at Mount Sinai, a prominent institution in breast cancer research and treatment, in this study that will enroll patients of diverse backgrounds, and continue to grow the body of data demonstrating the benefits of our approach.”

Champions TumorGrafts are a personalized approach used to guide physician treatment decisions for cancer patients. A piece of the patient’s living tumor is removed during surgery or biopsy and engrafted in immune-deficient mice. After the TumorGraft grows, still closely resembling the patient’s tumor, Champions Oncology tests drug treatments in the TumorGraft and measures the response. TumorGraft has demonstrated high rates of predictability using multiple therapies, including single-agent and combination, chemotherapy regimens and targeted biological drugs, with data recently published in Cancer and Clinical Cancer Research.

Every TumorGraft is preserved as a living sample for future patient use. These banked TumorGrafts can be re-grown and tested in the event of cancer progression or recurrence. They have been successfully utilized in most solid tumor types including colorectal, ovarian, lung, breast, sarcoma, pancreatic, stomach, esophageal and others.